Ophthalmology. Retina最新文献

{"title":"Progressive Macular Excavation in RD3 Mutation","authors":"Srikanta Kumar Padhy MD","doi":"10.1016/j.oret.2024.10.022","DOIUrl":"10.1016/j.oret.2024.10.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e60"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 3 Macular Neovascularization in Age-related Macular Degeneration","authors":"Riccardo Sacconi MD, PhD ,&nbsp;Paolo Forte MD ,&nbsp;Giulia Corradetti MD ,&nbsp;Eliana Costanzo MD ,&nbsp;Vittorio Capuano MD ,&nbsp;Elodie Bousquet MD ,&nbsp;Federico Beretta MD ,&nbsp;Serena Iannuzzi MD ,&nbsp;Maria Sole Polito MD ,&nbsp;Massimo Nicolò MD ,&nbsp;Mariacristina Parravano MD ,&nbsp;Eric Souied MD, PhD ,&nbsp;David Sarraf MD ,&nbsp;SriniVas Sadda MD ,&nbsp;Francesco Bandello MD ,&nbsp;Giuseppe Querques MD, PhD","doi":"10.1016/j.oret.2024.11.011","DOIUrl":"10.1016/j.oret.2024.11.011","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify baseline OCT predictors of the 3-year macular atrophy (MA) development for type 3 (T3) macular neovascularization (MNV) secondary to neovascular age-related macular degeneration (nAMD) treated by anti-VEGF therapy.</div></div><div><h3>Design</h3><div>Multicenter, retrospective, longitudinal study.</div></div><div><h3>Participants</h3><div>We included patients with treatment-naive T3 MNV secondary to nAMD at baseline, treated with anti-VEGF during a 3-year follow-up.</div></div><div><h3>Methods</h3><div>Patients were identified from 6 retinal referral institutions: (1) San Raffaele University, Milan, Italy; (2) University of Genova, Genova, Italy; (3) Doheny Eye Institute, Los Angeles; (4) Stein Eye Institute, Los Angeles; (5) University of Paris Est, Creteil, France; and (6) Istituto di Ricovero e Cura a Carattere Scientifico Bietti Foundation, Rome, Italy. Several baseline predictors of 3-year MA area were analyzed based on structural OCT and demographics.</div></div><div><h3>Main Outcome Measures</h3><div>Multivariate analysis to identify baseline independent predictors of the 3-year MA development for T3 MNV secondary to nAMD treated by anti-VEGF therapy.</div></div><div><h3>Results</h3><div>We included 131 eyes of 131 patients (mean age, 80 ± 6 years; 81% females). Best-corrected visual acuity was 0.49 ± 0.40 logarithm of the minimum angle of resolution (logMAR) at the baseline and significantly decreased to 0.59 ± 0.43 logMAR at the end of 3-year follow-up (<em>P</em> &lt; 0.001). Patients were treated with 11 ± 6 anti-VEGF injections and developed atrophy in 75% of cases (from 18% at the baseline). Eyes that developed 3-year MA were treated with a significantly lower number of injections compared with eyes without MA (9.9 ± 5.5 vs. 14.7 ± 7.2 injections, <em>P</em> &lt; 0.001). The most relevant independent predictors at baseline of MA area at 3-year follow-up were: area of MA at baseline (<em>P</em> &lt; 0.001), age-related macular degeneration phenotype (presence of reticular pseudodrusen) (<em>P</em> = 0.017), baseline presence of nascent geographic atrophy (<em>P</em> = 0.008), and the baseline presence of subretinal hyperreflective material (<em>P</em> = 0.002).</div></div><div><h3>Conclusions</h3><div>Macular atrophy development is a frequent complication of T3 MNV treated with anti-VEGF injections. Several factors could be considered baseline predictors of atrophy development during the anti-VEGF treatment.</div></div><div><h3>Financial Disclosure(s)</h3><div>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 546-555"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into Cataract Surgery Outcomes in Age-Related Macular Degeneration","authors":"Leopold Hössl ,&nbsp;Shirin Ashraf Vaghefi MD ,&nbsp;Tommes Riemer MD ,&nbsp;Payam Kabiri MD ,&nbsp;Theresa Bonaventura MD ,&nbsp;Anne Rübsam MD ,&nbsp;Antonia M. Joussen MD ,&nbsp;Oliver Zeitz MD","doi":"10.1016/j.oret.2024.11.018","DOIUrl":"10.1016/j.oret.2024.11.018","url":null,"abstract":"<div><h3>Purpose</h3><div>Cataract and age-related macular degeneration (AMD) share age as a main risk factor and thus have a high coincidence. Both conditions substantially reduce visual acuity. This study aimed to assess the impact of cataract surgery on visual acuity, retinal morphology, and VEGF inhibitor therapy in patients with AMD.</div></div><div><h3>Design</h3><div>This study was designed as a retrospective, monocentric, real-world study.</div></div><div><h3>Subjects</h3><div>Patients diagnosed with either dry AMD or neovascular AMD undergoing cataract surgery at Charité Campus Benjamin Franklin.</div></div><div><h3>Methods</h3><div>Treatment data were extracted from the Berlin Macular Registry. Best-corrected visual acuity (BCVA) and macular OCT parameters, including central retinal thickness (CRT), macular volume (MV), presence of macular edema, intraretinal or subretinal fluid, and pigment epithelial detachment were assessed.</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome measure was the postoperative BCVA. Secondary outcomes included postoperative CRT, MV, changes in qualitative OCT parameters, alterations in anti-VEGF–therapy interval, and postoperative complications.</div></div><div><h3>Results</h3><div>A total of 418 eyes of 418 patients were included in the analysis with a mean follow-up time of 18.8 (2–62) months. They were classified into a neovascular AMD (n = 85) and a dry AMD (n = 333) cohort. Mean BCVA improved significantly in the neovascular AMD cohort from 0.69 ± 0.45 logarithm of the minimum angle of resolution (logMAR) to 0.47 ± 0.42 (<em>P</em> &lt; 0.001) and in the dry AMD cohort from 0.53 ± 0.47 logMAR to 0.27 ± 0.32 (<em>P</em> &lt; 0.001) at the 2-month follow-up. Improvements in BCVA were sustained to the final visit (18.8 ± 19.5 months after surgery) with BCVA at 0.46 ± 0.38 logMAR (<em>P</em> &lt; 0.001) and 0.26 ± 0.34 logMAR (<em>P</em> &lt; 0.001), respectively. Temporary postoperative increases in CRT and MV were observed, reverting to preoperative levels by 6 months after surgery. The need for anti-VEGF therapy did not change postoperatively in patients with neovascular AMD.</div></div><div><h3>Conclusions</h3><div>Within this retrospective analysis, on average, patients with coincident AMD of all severity grades meeting the inclusion criteria benefited from cataract surgery. Transient increases in retinal thickness and MV returned to baseline within 6 months after surgery. The need for intravitreal injections in neovascular AMD subjects was unchanged after surgery. Overall, the study suggests no adverse long-term macular changes attributable to cataract surgery.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 527-536"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142771129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Widefield Swept-Source OCT Angiography of Takayasu Retinopathy","authors":"Yanping Zhou MD ,&nbsp;Jinhui Dai MD, PhD ,&nbsp;Yongjin Zhang MD","doi":"10.1016/j.oret.2024.10.008","DOIUrl":"10.1016/j.oret.2024.10.008","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e54"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Manifestations of Pallister-Killian Syndrome","authors":"Somya Kumari MD,&nbsp;Shivayan Srivastava MBBS,&nbsp;Shumaila Singh MBBS","doi":"10.1016/j.oret.2024.10.020","DOIUrl":"10.1016/j.oret.2024.10.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e59"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Melphalan versus Topotecan for Vitreous Seeds in Retinoblastoma","authors":"Ayushi Agarwal MD,&nbsp;Vishakha Tanna MD,&nbsp;Vijitha S. Vempuluru MD,&nbsp;Vishal Raval MD,&nbsp;Swathi Kaliki MD","doi":"10.1016/j.oret.2024.11.010","DOIUrl":"10.1016/j.oret.2024.11.010","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the outcomes of intravitreal melphalan (IVit-M) versus intravitreal topotecan (IVit-T) for vitreous seeds (VS) in retinoblastoma (RB).</div></div><div><h3>Design</h3><div>Retrospective interventional study.</div></div><div><h3>Participants</h3><div>Patients of RB with VS receiving intravitreal chemotherapy (IVit-C) between December 2012 and December 2022, at a single quaternary ocular oncology referral center.</div></div><div><h3>Intervention</h3><div>Intravitreal melphalan injection of 25 μg/0.1 mL in 25 eyes and IVit-T of 30 μg/0.15 mL in 39 eyes.</div></div><div><h3>Main Outcome Measures</h3><div>Resolution of VS, globe salvage, IVit-C–related complications.</div></div><div><h3>Results</h3><div>The mean age at presentation was 28 months (median, 24 months; range, 4–144 months) for the IVit-M group and 25 months (median, 24 months; range, 2–60 months) for the IVit-T group. At the time of initiation of intravitreal injection, the VS belonged to type 1 (1 [4%] vs. 1 [3%]), type 2 (9 [36%] vs. 14 [36%]), type 3 (8 [32%] vs. 18 [46%]), or a combination of these (7 [28%] vs. 6 [15%]) in IVit-M and IVit-T groups, respectively. Complete resolution of VS after IVit-C was seen in 22 (92%) and 28 (72%) eyes (<em>P</em> = 0.069) in IVit-M and IVit-T groups, respectively. At a mean follow-up period of 44 months after the first IVit-C injection in the IVit-M group and 19 months in the IVit-T group, globe salvage was higher in the IVit-T group (77%) than in the IVit-M group (60%, <em>P</em> = 0.148), respectively. Posterior segment complications were significantly higher in the IVit-M group than in the IVit-T group (<em>P</em> &lt; 0.001). These included retinal pigment epithelial atrophy (<em>P</em> &lt; 0.001), optic atrophy (<em>P</em> &lt; 0.001), vascular attenuation (<em>P</em> &lt; 0.001), and retinal/subretinal hemorrhages (<em>P</em> = 0.004).</div></div><div><h3>Conclusions</h3><div>Intravitreal topotecan is as efficacious as IVit-M for controlling VS in RB, with a better safety profile in pigmented Asian Indian eyes.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 589-597"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Obstructive Sleep Apnea and Age-related Macular Degeneration Development and Progression","authors":"Ahmed M. Alshaikhsalama BS ,&nbsp;Amer F. Alsoudi MD ,&nbsp;Karen M. Wai MD ,&nbsp;Euna Koo MD ,&nbsp;Prithvi Mruthyunjaya MD, MHS ,&nbsp;Ehsan Rahimy MD","doi":"10.1016/j.oret.2024.12.004","DOIUrl":"10.1016/j.oret.2024.12.004","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the risk of age-related macular degeneration (AMD) development and progression in individuals with diagnosed obstructive sleep apnea (OSA).</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Before propensity score matching (PSM), 60 652 and 1 173 723 individuals with OSA or not, respectively, were included in the study. After PSM and applying inclusion/exclusion criteria, 58 700 individuals in each cohort were subsequently analyzed.</div></div><div><h3>Methods</h3><div>Data were collected using TriNetX, a deidentified electronic health records research network. Individuals with an <em>International Classification of Diseases, 10th Revision</em>, code for OSA confirmed with polysomnography and an additional code for continuous positive airway pressure use were compared with individuals without diagnosed OSA (control cohort) for the development of main outcome measures at 5 years. Secondary analyses were included to assess nonadvanced AMD progression in individuals with and without diagnosed OSA at 5 years.</div></div><div><h3>Main Outcome Measures</h3><div>The main outcome measures were the incidence of AMD, macular hemorrhage, legal blindness, and requiring anti-VEGF intervention at 5 years. Individuals with nonadvanced AMD with and without an OSA diagnosis were separately analyzed for progression to late AMD and the development of macular hemorrhage, legal blindness, and requiring anti-VEGF therapy at 5 years.</div></div><div><h3>Results</h3><div>At 5 years, individuals with diagnosed OSA had a significantly elevated risk of nonexudative AMD (hazard ratio [HR], 2.64; 95% confidence interval [CI], 2.37–2.96; <em>P</em> &lt; 0.001), exudative AMD (HR, 2.48; 95% CI, 1.99–3.11; <em>P</em> = 0.002), and requiring anti-VEGF therapy (HR, 2.85; 95% CI, 2.26–3.59; <em>P</em> &lt; 0.001) compared with the control cohort. In the secondary analysis, individuals with nonadvanced AMD with diagnosed OSA were associated with an elevated risk of geographic atrophy (HR, 7.00; 95% CI, 4.47–11.0; <em>P</em> = 0.03), exudative AMD (HR, 2.87; 95% CI, 2.37–3.48; <em>P</em> = 0.03), and requiring anti-VEGF injections (HR, 4.72; 95% CI, 3.59–6.22; <em>P</em> = 0.02) compared with those with nonadvanced AMD without diagnosed OSA.</div></div><div><h3>Conclusions</h3><div>In a large, heterogeneous database, an elevated risk of developing AMD and progression to later stages of the disease was observed among individuals with diagnosed OSA.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 537-545"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Risks of Endophthalmitis after 25-gauge Vitrectomy Surgery over a 14-year Period","authors":"Chase W. Miller BS ,&nbsp;Anja Rabljenovic BS ,&nbsp;Cassie Papproth BS ,&nbsp;Harrison Sciulli, MD ,&nbsp;Sean Platt, MD ,&nbsp;David G. Miller MD","doi":"10.1016/j.oret.2024.11.019","DOIUrl":"10.1016/j.oret.2024.11.019","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;To analyze endophthalmitis characteristics and risks after a 25-gauge vitrectomy or microincision vitrectomy surgery (MIVS).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Retrospective.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Subjects&lt;/h3&gt;&lt;div&gt;Post-MIVS endophthalmitis patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The records of a private, retina practice and an ambulatory surgery center (ASC) were searched from January 2010 to April 2024, for post-MIVS endophthalmitis cases. Data collected were age, sex, surgeon, first assistant, procedure, surgery date, surgical platform, symptom onset date, preoperative visual acuity (VA), infection presentation VA, 90-day postoperative VA, case length, vitreous substitute (balanced salt solution [BSS], gas, air, or oil), sclerotomy suture use, surgical complications, vitreous sampling culture growth, and endophthalmitis treatment. Logarithm of the minimum angle of resolution-converted VAs were analyzed from preoperative to 90-day postoperative endophthalmitis. The procedures included pars plana vitrectomy (PPV) for macular pucker, vitreous opacity or hemorrhage, with endolaser, for retinal detachment (RD), and macular hole (MH). An all MIVS cohort to analyze patient sex, surgeon caseload, platforms, and procedure was created for incidence and statistical calculations. A secondary comparison, April to May 2023, was performed analyzing endophthalmitis per vitreous substitute via chi-square test for independence.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;Endophthalmitis post-MIVS.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The ASC saw 27 of 24 987 (0.11%) post-MIVS endophthalmitis cases. None of the surgeries recorded intraoperative complications. The average time between surgery and presentation was 2.88 ± 2.66 days. Mean VA preoperatively and 90-day postoperatively were calculated, 0.630 ± 0.717 and 1.041 ± 0.895, respectively (0.286 ± 0.437 mean difference). The individual surgeon incidence of endophthalmitis was not found to be significant in this study. Endophthalmitis incidence per PPV is 13 of 5545 (0.23%) postmacular pucker, 7 of 4619 (0.15%) vitreous opacity or hemorrhage, 4 of 2350 (0.17%) endolaser, 3 of 9834 (0.03%) RD, and 0 (0.0%) MH (&lt;em&gt;P&lt;/em&gt; = 0.0004). Of 435 PPVs performed April to May 2023, vitreous substitutes were 183 (42%) gas-filled, 169 (38.9%) BSS-filled, 45 (10.3%) oil-filled, and 38 (8.7%) air-filled. Of the 27 endophthalmitis cases, 23 (85.2%) used BSS, 1 (3.7%) oil-filled, and 2 (7.4%) air-filled. A significant statistical association between vitreous substitute and endophthalmitis incidence via chi-square testing (&lt;em&gt;P&lt;/em&gt; &lt; 0.0001) was found.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;This study found a 1 of 910 (0.11%) incidence of endophthalmitis post-25-gauge MIVS. Both vitreous substitute and procedure type showed a significant risk of endophthalmitis. Although endophthalmitis risk is low overall, the potential for severe vision loss warrants further examination into contri","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 556-563"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142771128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose Intravitreal Topotecan for Perifoveal Recurrence of Retinoblastoma","authors":"Madison M. Woods BA,&nbsp;Rolika Bansal MD,&nbsp;Carol L. Shields MD","doi":"10.1016/j.oret.2024.10.010","DOIUrl":"10.1016/j.oret.2024.10.010","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e55"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and Need for Additional Interventions after Intravitreal Bevacizumab for Retinopathy of Prematurity","authors":"Ally J. Sun BS ,&nbsp;Brisa Y. Garcia BS ,&nbsp;Hank Patrick MD ,&nbsp;Yu-Guang He MD ,&nbsp;Angeline L. Wang MD","doi":"10.1016/j.oret.2024.11.014","DOIUrl":"10.1016/j.oret.2024.11.014","url":null,"abstract":"<div><h3>Objective</h3><div>This study investigated the outcomes of premature infants diagnosed with retinopathy of prematurity (ROP) that were treated with intravitreal bevacizumab (IVB), as well as the need for further treatment after injection.</div></div><div><h3>Design</h3><div>Retrospective case series.</div></div><div><h3>Participants</h3><div>Seventy-three premature infants born between 2016 and 2020 at a large county hospital and children’s hospital.</div></div><div><h3>Methods</h3><div>Chart review was performed and patient demographics, neonatal intensive care unit (NICU) course, ROP exams, and treatment were collected.</div></div><div><h3>Main Outcome Measures</h3><div>Rates of recurrent ROP disease, complete vascularization, persistent avascular retina (PAR), as well as rates of secondary and tertiary laser photocoagulation, IVB, or pars plana vitrectomy.</div></div><div><h3>Results</h3><div>Infants included in this study were born at a median gestational age (GA) of 24.6 weeks (range, 23.0–30.1) and a median birth weight of 670 g (range, 370–1080). Patients received their IVB injection at a median postmenstrual age (PMA) of 36.4 weeks (range, 16.0–87.9). Five patients died during their NICU course and did not have long-term follow-up. Of the remaining patients, 24 (33%) experienced complete vascularization after 1 injection; 13 (18%) experienced regression followed by disease recurrence necessitating additional interventions; 5 (7%) had persistent disease and did not experience any regression requiring laser treatment or a second IVB injection; and 26 (36%) experienced regression with PAR. Patients with persistent or recurrent ROP had a significantly lower GA than other patients in the study (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>For one-third of premature patients, 1 IVB injection was sufficient for ROP regression and complete vascularization of the retina. The remaining patients required some form of additional intervention after their injection, with a majority receiving laser for PAR. One-fifth of patients experienced disease recurrence up to 58 weeks PMA. Future studies should be performed on PAR prevalence and presentations to explore how long patients with PAR should be monitored.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 564-569"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}